Coming Udencya Approval Likely A Negative Event For Amgen (AMGN) - Citi
Tweet Send to a Friend
Citi analyst, Robyn Karnauskas, reiterated her Neutral rating on shares of Amgen (NASDAQ: AMGN) ahead of a negative catalyst in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


